Coronavirus Notebook: EMA Expects First Vaccine Efficacy Data Soon, ACT-Accelerator Needs Urgent Funding
Executive Summary
Talks are continuing on COVID-19 vaccine supply in the EU, with Pfizer/BioNTech’s BNT-162 the latest in the frame for the delivery of 200 million doses. The European Commission has also said that if the vaccines fail to perform, any money paid in advance purchase deals should go towards further research.
You may also be interested in...
Coronavirus Notebook: Moderna Renounces COVID-19 Patents, China Joins COVAX
The CEPI coalition plans a global network to assess and compare the immunological responses generated by COVID-19 vaccine candidates, and a trial gets under way to test whether the BCG vaccine can afford some immunity against coronavirus.
EMA Starts ‘Rolling Review’ Of AstraZeneca’s COVID-19 Vaccine
The European Medicines Agency says its rolling review tool should speed up the evaluation of AstraZeneca’s COVID-19 vaccine.
EMA Pushes For More EU Support For COVID-19 Vaccine Work
Preparing for the assessment and post-approval monitoring of COVID-19 vaccines is taking up a lot of resources at the EMA, which has called on the European Commission to provide more support for such activities. The agency has also confirmed that no data have yet been submitted for its planned rolling reviews of potential vaccines.